Clinical trial
Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated…
NCT00478465 · Stanford University, Other · Completed
Key facts
| NCT number | NCT00478465 |
|---|---|
| Title | Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV) |
| Official title | A Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Valganciclovir (Valcyte) in Patients Experiencing Chronic Fatigue Syndrome With Elevated Antibody Titers Against Human Herpesvirus-6 (HHV-6) and Epstein-Barr Virus (EBV) |
| Lead sponsor | Stanford University, Other |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Chronic Fatigue Syndrome |
| Intervention type | Drug |
| Interventions | valganciclovir |
| Enrollment | 30 |
| Start date | May 1, 2007 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | May 24, 2007 |
| Last update posted | May 27, 2022 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: